Pangea Biomed and FibroFighters have partnered to combat fibrolamellar carcinoma (FLC), a rare liver cancer primarily affecting young individuals without a liver disease history. Pangea’s ENLIGHT, which uses unsupervised learning and tumor transcriptomics, will aid in identifying tailored treatments for FLC. This partnership aims to enhance treatment strategies by correlating predictions with actual outcomes. A notable case published in the Journal for ImmunoTherapy of Cancer demonstrated complete remission in an FLC patient using ENLIGHT-guided therapy, despite lacking typical biomarkers for the used drugs.
Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.
Fibrolamellar carcinoma (FLC) is a rare liver cancer that typically presents in young adolescents and young adults at a median age of 22 who have no history of liver disease. There is no clear standard of care for the disease, and in the setting of metastatic disease, 5-year survival rates are approximately 39 percent
Expanding Horizons in the Treatment of Fibrolamellar Carcinoma
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Since FLC makes up about 1% of all primary liver cancers, there is limited data on the disease, which impedes treatment,” said Pangea CEO Tuvik Beker, Ph.D. “Fortunately, by design, ENLIGHT can surface relevant insights specific to a patient’s tumor even without significant training datasets.”
Using ENLIGHT, which leverages unsupervised learning and sequenced tumor transcriptomics, Pangea will suggest treatments for FLC patients that FibroFighters work with, compare treatment response predictions against treatment outcomes, as well as with ex-vivo models, and refine models for treatment response and resistance. In December 2022, Pangea published a case study in the Journal for ImmunoTherapy of Cancer on the ENLIGHT-matched treatment of an FLC patient. Despite common biomarkers for immune checkpoint blockade (ICB) coming back negative, the patient went into complete remission after being treated with an ENLIGHT-matched combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1).
Source: Hitconsultant
